Cingulate Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a CING research report →
Companywww.cingulate.com
Cingulate Inc. , a clinical-stage biopharmaceutical company, focuses on the development of product candidates for the treatment of attention-deficit/hyperactivity disorder. The company's lead product candidates are CTx-1301 (dexmethylphenidate), which is in phase 3 clinical trial, and CTx-1302 (dextroamphetamine) for the treatment of attention-deficit/hyperactivity disorders.
- CEO
- Shane J. Schaffer
- IPO
- 2021
- Employees
- 13
- HQ
- Kansas City, KS, US
Price Chart
Valuation
- Market Cap
- $25.96M
- P/E
- -1.62
- P/S
- 0.00
- P/B
- 2.40
- EV/EBITDA
- -0.34
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -368.38%
- ROIC
- -91.87%
Growth & Income
- Revenue
- $0 · 0.00%
- Net Income
- $-22,449,911 · -44.41%
- EPS
- $-4.13 · 59.51%
- Op Income
- $-19,938,108
- FCF YoY
- 6.73%
Performance & Tape
- 52W High
- $11.89
- 52W Low
- $3.20
- 50D MA
- $6.10
- 200D MA
- $4.91
- Beta
- -0.81
- Avg Volume
- 528.66K
Get TickerSpark's AI analysis on CING
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| Mar 31, 26 | Silva Raul R. | other | 3,422 |
| Mar 9, 26 | Silva Raul R. | other | 4,526 |
| Mar 9, 26 | Silva Raul R. | other | 1,828 |
| Mar 9, 26 | Schaffer Shane J. | other | 6,862 |
| Mar 9, 26 | Schaffer Shane J. | other | 2,959 |
| Mar 9, 26 | Callahan Jennifer L. | other | 15,329 |
| Mar 9, 26 | Callahan Jennifer L. | other | 6,427 |
| Mar 9, 26 | Patel Nilay Dahyabhai | other | 5,475 |
| Mar 9, 26 | Patel Nilay Dahyabhai | other | 2,086 |
| Mar 9, 26 | Brams Matthew | other | 4,526 |
Our CING Coverage
We haven't published any research on CING yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate CING Report →